Psychopharmacology in Medical Conditions:
Rapid Decision Guide
Medication Safety in Medical Conditions
Quick-reference safety guidance for prescribing psychotropic medications in patients with renal, hepatic, cardiac, and other medical comorbidities.
Psychotropics & Cardiac Safety (QTc)
Quickly check QTc risk and cardiac safety across psychotropics with clear, tiered guidance.
View Guide →Psychotropics in Renal Impairment
Dose-by-eGFR guidance across drug classes — including lithium and dialysis.
View Guide →Psychotropics in Hepatic Impairment
Child-Pugh–based dosing, hepatotoxic agents to avoid, and the encephalopathy traps.
View Guide →Psychotropics in Seizure Disorders
Seizure-threshold ranking, enzyme-inducing interactions, and safe agent selection.
View Guide →Psychotropics in HIV/AIDS
Booster and inducer interactions (ritonavir, efavirenz) plus the psychiatric syndromes of HIV.
View Guide →Psychotropics in Organ Transplant
Immunosuppressant interactions (tacrolimus/cyclosporine, CYP3A4) and QTc overlap.
View Guide →Psychotropics in Pulmonary Disease
Respiratory reserve & the smoking–CYP1A2 lever — benzodiazepine risk in COPD, and clozapine/olanzapine shifts on cessation.
View Guide →Full Access Available to Academy Members
This clinical series is part of the Psychiatry Education Forum Academy and is available exclusively to enrolled members.
Designed for busy clinicians, the Academy provides structured, high-yield, point-of-care content across psychopharmacology — so you can make faster, more confident decisions in real-world practice.
If you're looking for rapid medication-level guidance, standardized frameworks, and clinic-ready tools you can actually use during patient care, this is built for you.
Join the Academy to unlock full access to this and our 500+ clinically relevant chapters.
Yearly Plan
- Best value
- Maximum savings
- For committed learners
- Most popular
Discounts available for: Residents & Students only.
Email your student information (program details and confirmation of student status) to:
[email protected]
Responses